Edgewise Therapeutics: director Jonathan C Fox received 308 shares

What happened Jonathan C Fox, a director of Edgewise Therapeutics, received 308 shares through the grant and release of restricted stock units on Oct 1, 2026. The filing reports a price of $0.00 per share for a total reported value of $0. The award was a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Directors Compensation Policy, as amended.

Key details

• Transaction date and type: Oct 1, 2026; award/grant (code A); price $0.00 per share; 308 shares.
• Shares owned after the transaction: not reported in this filing.
• Footnote: consists of restricted stock units granted and released to the reporting person on Oct 1, 2026, as a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Directors Compensation Policy, as amended.
• Filing date: Oct 2, 2026. The filing does not indicate it was late.

Why it may matter

• This was a grant and release of restricted stock units, not a market purchase or sale.
• The award was compensation to an outside director under the company's outside directors compensation policy.
• A filing does not show why the insider traded or why the company acted.